Evaluation of a Suspended Personal Radiation Protection System vs. Conventional Apron and Shields in Clinical Interventional Procedures  

作　　者：Clare Savage Thomas M. Seale IV Cathryn J. Shaw Bruner P. Angela Daniel Marichal Chet R. Rees 

机构地区：[1]Department of Radiology, Medical Center, Baylor University, Dallas, USA [2]River City Imaging, San Antonio, USA

出　　处：《Open Journal of Radiology》2013年第3期143-151,共9页放射学期刊（英文）

摘　　要：Purpose: This clinical study compares conventional lead aprons and ancillary shields to a functionally weightless personal overhead-supported system with expanded coverage. Materials and Methods: Primary operators performed procedures (N = 126, fluoroscopy minutes = 1209) using one of 2 methods of radiation protection and wearing dosimeters on multiple body locations. Method “LAS” (Lead-Apron+Shields): lead skirt, vest, thyroid shield, with 100% use of under-table shield, side shield, and mobile suspended lead-acrylic shield. Method “Zgrav”: ZeroGravity system (CFI Medical Solutions) with variable use of shielding. The studied early model moving with the operator had a curved lead-acrylic head shield (0.5 mm Pb) and expansive lead apron (0.5 - 1.0 mm Pb) that covered leg to distal calf and proximal arm to elbow, and a drape that permitted sterile entry and exit. Study was institutional review board approved and HIPPA-compliant. Results: Measured with a sensitive electronic dosimeter, eye exposures were 99% (P 0.001) reduced for Zgrav with upgraded face shield vs. LAS, regardless of use or non-use of suspended shield with Zgrav. With optically stimulated luminescence (OSL) dosimeters, operator exposures, standardized to minutes of fluoroscopy and Fluoroscopic Patient Dose Area Product, were reduced by 87% - 100% for eye & head, neck, humerus, and tibia (Zgrav vs. LAS). Overall eye & head exposure reduction for entire study was 94%. Non-equivalence of torso exposures was not demonstrated. A brief user survey showed ergonomic advantages of Zgrav. Conclusion: Compared to conventional lead aprons with shields, the suspended system provided superior operator protection during interventional fluoroscopy, allowing operators to perform procedures without potentially obstructive shields.Purpose: This clinical study compares conventional lead aprons and ancillary shields to a functionally weightless personal overhead-supported system with expanded coverage. Materials and Methods: Primary operators performed procedures (N = 126, fluoroscopy minutes = 1209) using one of 2 methods of radiation protection and wearing dosimeters on multiple body locations. Method “LAS” (Lead-Apron+Shields): lead skirt, vest, thyroid shield, with 100% use of under-table shield, side shield, and mobile suspended lead-acrylic shield. Method “Zgrav”: ZeroGravity system (CFI Medical Solutions) with variable use of shielding. The studied early model moving with the operator had a curved lead-acrylic head shield (0.5 mm Pb) and expansive lead apron (0.5 - 1.0 mm Pb) that covered leg to distal calf and proximal arm to elbow, and a drape that permitted sterile entry and exit. Study was institutional review board approved and HIPPA-compliant. Results: Measured with a sensitive electronic dosimeter, eye exposures were 99% (P 0.001) reduced for Zgrav with upgraded face shield vs. LAS, regardless of use or non-use of suspended shield with Zgrav. With optically stimulated luminescence (OSL) dosimeters, operator exposures, standardized to minutes of fluoroscopy and Fluoroscopic Patient Dose Area Product, were reduced by 87% - 100% for eye & head, neck, humerus, and tibia (Zgrav vs. LAS). Overall eye & head exposure reduction for entire study was 94%. Non-equivalence of torso exposures was not demonstrated. A brief user survey showed ergonomic advantages of Zgrav. Conclusion: Compared to conventional lead aprons with shields, the suspended system provided superior operator protection during interventional fluoroscopy, allowing operators to perform procedures without potentially obstructive shields.

关 键 词：RADIATION Protection RADIATION FLUOROSCOPY 

分 类 号：R73[医药卫生—肿瘤]